Fundraising FoxAuron Therapeutics
Newton, US · Founded 2018 · Delaware corporation · 7 known investors
Find your way into Auron Therapeutics
Sign up to see every warm intro you have to Auron Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Auron Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Auron Therapeutics was founded in 2018 by Katharine Yen and Kate Yen.
KY
Katharine YenCo-founder
KY
Kate YenFounder, CEOKate Yen holds a Ph.D. in molecular biology from UCLA and conducted post-doctoral research on prostate cancer mechanisms, developing a transgenic mouse model of the disease. She later worked in drug discovery at Merck Research Laboratories and Agios Pharmaceuticals, focusing on oncology target identification and validation.
CG
Christopher GuiffreExecutive
Board
AL
Alon LazarusBoard director
AF
Anna FrenchBoard DirectorAnna French holds a D.Phil. from the University of Oxford, where she researched the hematological differentiation of human iPS cells, and a BSc in Biochemistry from the University of Bristol; she has published extensively in stem cell research. Her career includes healthcare management consulting at the Boston Consulting Group, a role at Qiming Venture Partners USA, and leadership of the CASMI Translational Stem Cell Consortium, an Oxford–UCL partnership focused on cell therapy commercialization.
AC
ES
PO
Pini OrbachBoard director
SM
Serge MesserlianMember Board of DirectorsSerge Messerlian is a director at Auron Therapeutics, an AI-native drug development company focused on serious chronic diseases such as cancer, autoimmune disorders, and rare diseases. His background spans biotech venture finance and board directorship, R&D leadership from preclinical through Phase I–IV, P&L and M&A integration leadership, and therapeutic expertise across oncology, hematology, immunology, cardio-pulmonary, and rare disease, along with market access, pricing, and reimbursement experience across the US, Canada, and EU5.
VR
Victoria RichonBoard director
BD
Briggs Duncan MorrisonBoard director
Investors · 7
DCVC (Data Collective)listed by DCVC (Data Collective)Palo Alto · $5M – $25M
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Qiming Venture Partners USAlisted by Qiming Venture Partners USACambridge
How we know: Qiming Venture Partners USA's portfolio page · Not right? Tell us
Apollo Health VenturesreportedBerlin
How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
DCVC BioreportedPalo Alto
How we know: a partner's Signal profile · funding news · Not right? Tell us
Polaris PartnersreportedBoston · $500K – $5Mvia Alexandra Cantley · board
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$88.9M disclosed across 5 rounds · 2018–2026
▶$7.1MraisedAug 2026 · 14 investors · BiotechnologyRule 506(b)
▶$7.1MraisedAug 2026 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Katharine YenExecutive Officer, Director
- Alexandra CantleyDirector
- Briggs Duncan MorrisonDirector
- Anna FrenchDirector
- Pini OrbachDirector
- Serge MesserlianDirector
- Victoria RichonDirector
- Offering amount
- $12M
- Amount sold
- $7.1M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27.3MraisedDec 2025 · 16 investors · BiotechnologyRule 506(b)
▶$27.3MraisedDec 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Briggs Duncan MorrisonDirector
- Pini OrbachDirector
- Katharine YenExecutive Officer, Director
- Alexandra CantleyDirector
- Victoria RichonDirector
- Anna FrenchDirector
- Serge MesserlianDirector
- Offering amount
- $42.3M
- Amount sold
- $27.3M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$38.4MraisedOct 2023 · 10 investors · BiotechnologyRule 506(b)
▶$38.4MraisedOct 2023 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher GuiffreExecutive Officer
- Alon LazarusDirector
- Anna FrenchDirector
- Katharine YenExecutive Officer, Director
- Victoria RichonDirector
- Briggs Duncan MorrisonDirector
- Alexandra CantleyDirector
- Eric ShiozakiDirector
- Offering amount
- $48.2M
- Amount sold
- $38.4M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$15.4MraisedDec 2020 · 25 investors · BiotechnologyRule 506(b)
▶$15.4MraisedDec 2020 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac CiechanoverDirector
- Katharine YenExecutive Officer, Director
- John Duncan HiggonsDirector
- Alon LazarusDirector
- Anna FrenchDirector
- Offering amount
- $15.4M
- Amount sold
- $15.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$660KraisedJul 2018 · 8 investors · BiotechnologyRule 506(b)
▶$660KraisedJul 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Katharine YenExecutive Officer, Director
- John Duncan HiggonsDirector
- Offering amount
- $1.5M
- Amount sold
- $660K
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Auron Therapeutics went on to found or lead other companies.
Frequently asked questions
- Who founded Auron Therapeutics?
- Auron Therapeutics was founded by Katharine Yen, Kate Yen in 2018.
- Who are Auron Therapeutics's investors?
- Auron Therapeutics's investors include DCVC (Data Collective), Qiming Venture Partners USA, Apollo Health Ventures, BrightEdge, DCVC Bio, Polaris Partners, Qiming Venture Partners.
- How much funding has Auron Therapeutics raised?
- Auron Therapeutics has disclosed $88.9M raised across 5 rounds.
- Where is Auron Therapeutics headquartered?
- Auron Therapeutics is headquartered in Newton, US.